ArticleAvicenna journal of phytomedicine
Hepatoprotective effects of cinnamaldehyde against high-fat diet-induced liver damage.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder worldwide, affecting 30-40% of adults. High-fat diets contribute significantly to NAFLD by promoting hepatic lipid accumulation, oxidative stress, and inflammation. In this context, cinnamaldehyde (CNMA) has emerged as a promising hepatoprotective agent due to its antioxidant, anti-inflammatory, and lipid-regulatory properties. Materials and Methods: Male Wistar rats were randomly assigned to four groups (n=6 per group): (A) Control; (B) HFD; (C) Control+CNMA; and (D) HFD+CNMA. CNMA was administered orally at 20 mg/kg body weight for 16 weeks simultaneously with HFD. At the end of the study, rats were fasted for 12-14 hr and anesthetized with sodium pentobarbital (60 mg/kg, intraperitoneal) for serum, liver, and visceral adipose tissues collection. Biochemical analyses included serum liver enzymes, lipid profiles, hepatic triglyceride levels, and oxidative stress markers (nitric oxide metabolites; NOx, and malondialdehyde; MDA). Histopathological evaluation was performed on H&E (Hematoxylin and Eosin)-stained liver sections. Results: HFD feeding induced significant hepatic injury and metabolic dysfunction in rats, characterized by elevated AST (Aspartate aminotransferase) and ALT (Alanine aminotransferase) levels, increased liver and fat pad weights, and enhanced oxidative stress. CNMA treatment significantly reduced these parameters, resulting in lower serum liver enzymes, decreased hepatic triglyceride content, reduced adiposity (notably mesenteric fat), and ameliorated oxidative stress. Histopathological findings confirmed a reduction in micro- and macrovesicular steatosis with CNMA. Conclusion: CNMA significantly protected against HFD-induced hepatic injury by reducing serum AST and ALT, hepatic triglycerides, visceral adiposity, and oxidative stress and inflammatory markers, as confirmed by histopathology. It suggests the therapeutic potential of CNMA for NAFLD and related metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.